Terminally exhausted CD8+ T cells, marked by CD39+ PD1+ or TIM3+ PD1+, at the tumor site were significantly suppressed by cell adjuvant therapy (Fig. S3, D and E). This evidence concerns the gene ENTPD1 and neoplasm.